Product Data Sheet

Product Name: NecroX-5
Cat. No.: GC31873

Chemical Properties

Cas. No.	1383718-29-3		
SMILES	O=S1(CCN(CC2=CC3=C(NC(C4=CC=CC=C4)=C3)C(NCC5CCOCC5)=C2)CC1)=O.CS(=O)(O)=O.CS(=O)(O)=O		
Formula	$C_{27}H_{39}N_3O_9S_3$	M.Wt	645.81
Solubility	DMSO : 170 mg/mL (263.24 mM)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			



Background

NecroX-5 is a derivative of the NecroX, reduces intracellular calcium concentration, and possesses anti-inflammatory and anti-cancer activity.

NecroX-5 (10 or 40 μM) inhibits breast cancer cell migration, which is correlated with mitoROS

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

reduction, and mediated by AKT inhibition. NecroX-5 (10 μM) decreases intracellular calcium concentration in 4T1 cells by blocking Ca2+ influx, which mediated the inhibition of cell migration, AKT downregulation and the reduction of mitochondrial ROS levels[1]. NecroX-5 (10 μM) treatment for 24 h, effectively decreases the increased TNFα, TGFβ1, pSmad2 and the expression of Dcn in LPS-stimulated H9C2 cells[2].

NecroX-5 (2.5 mg/kg, everyday other day) inhibits breast cancer cell metastasis in TUBO-P2J tumour-bearing mice[1].

[1]. Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int J Oncol. 2017 Jan;50(1):185-192. [2]. Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14.